ECEthan J. Cannon

Ethan J. Cannon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ethan J. Cannon has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Association of air pollution exposure and risk of incident atrial fibrillation: The multi-ethnic study of atherosclerosis

    by Ethan J. Cannon, Joel D. Kaufman, Thomas R. Austin, Jeffrey R. Misialek, Susan R. Heckbert, David R. Jacobs, Pamela L. Lutsey

  • Open Access

    Semaglutide vs . liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

    by Ethan J. Cannon, Wendy Wang, Faye L. Norby, Rob F. Walker, Shalini Kulasingam, Lisa S. Chow, Joel F. Farley, Pamela L. Lutsey

    Aims: The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear. Methods: We employed an active comparator, new user design to emulate a target trial using data from MarketScan claims databases. Enrolees free of diabetes and CVD prescribed semaglutide or liraglutide during 2021–2023 were matched 1:1. Primary endpoints included incident diabetes and CVD (myocardial infarction, heart failure or stroke). We used Cox regression adjusted for a propensity score reflective of comorbidities and medication use. Results: We matched 57 456 GLP‐1 RA users (mean age 45; 83% female). Over 1‐year mean follow‐up, we observed 1104 diabetes events and 57 CVD events. After regression adjustment, semaglutide users had 12% lower risk of diabetes (hazard ratio [HR]: 0.88; 95% CI: 0.78, 0.99). For this endpoint, the proportional hazards assumption was violated ( p < .0001), so results were stratified by follow‐up time. During the first 6 months of follow‐up, semaglutide use was not associated with risk of diabetes compared with liraglutide use (HR: 0.99 [0.82–1.18]), but a significant association was present thereafter (HR: 0.80 [0.68, 0.94]). We did not detect a difference in risk of CVD events (HR: 1.25 [0.74–2.11]). Conclusions: In this real‐world study, semaglutide users had lower risk of incident diabetes compared with liraglutide users. Additional research is needed to elucidate comparative effectiveness of these drugs for cardiovascular risk.


  • Associations between plasma levels of coagulation factors VIII and IX and incident cardiovascular disease and mortality: systematic review and meta-analysis

    by Katie Harris, Mark Woodward, Aaron R. Folsom, Pamela L. Lutsey, Ethan Cannon, Neil A. Zakai, Mary Cushman, Nels C. Olson, Nithya Kannan, Ryan Packer, et al.


  • Dairy Intake and Coronary Artery Calcification: The Coronary Artery Risk Development in Young Adults (CARDIA) Prospective Cohort Study

    by Ethan J Cannon, David R Jacobs, Lyn M Steffen, Mark J Pletcher, James M Shikany, Philip Greenland, Felipe V Martignoni, Pamela J Schreiner, Michael Miedema


  • Association of Body Mass Index in Late Life, and Change from Midlife to Late Life, With Incident Dementia in the ARIC Study Participants

    by Ethan J. Cannon, B. Gwen Windham, Michael Griswold, Priya Palta, David S. Knopman, Sanaz Sedaghat, Pamela L. Lutsey

    Midlife obesity is a risk factor of dementia, but late-life obesity has been associated with lower dementia risk. We investigated this paradox by exploring the relationship between late-life body mass index (BMI) category and dementia, with and without considering midlife to late-life BMI change. This observational cohort study included participants of the community-based Atherosclerosis Risk in Communities (ARIC) study who were dementia-free at visit 5 (2011-2013). Dementia was ascertained by expert-adjudicated, algorithmic classification from an in-person neuropsychological battery, as well as telephone interviews and International Classification of Diseases codes from medical records. We first assessed the association of incident dementia with visit 5 BMI categories (normal weight, overweight, obese). Next, we used a cross-classification of visit 5 BMI categories with visit 4-visit 5 BMI change (decrease [loss of ≥2 kg/m2], increase [gain of ≥2 kg/m2], or stable [loss or gain of 2]) occurring during the 15 years before baseline. Cox regression was used. A total of 5,129 participants were included in the study (59% female; 22% identified as Black; mean (standard deviation) age at visit 5 of 75 (5) years). Over 8 years of follow-up, 20% of the sample developed dementia (n = 1,026). After covariate adjustment, participants with high late-life BMI had a lower risk of dementia; the hazard ratio (95% CI) was 0.86 (0.73-1.00) for overweight and 0.81 (0.68-0.96) for obesity. In stratified models, elevated dementia risk was observed only for participants of each late-life BMI category whose BMI had decreased from midlife to late life. Compared with normal-weight individuals who had maintained BMI from midlife to late life, the hazard ratio (95% CI) for those with BMI loss was 2.08 (1.62-2.67) for normal-weight individuals, 1.62 (1.25-2.10) for those with overweight, and 1.36 (1.00-1.85) for those with obesity. Our results provide insight into the dementia obesity paradox at older ages, tempering a causal interpretation of high late-life BMI as protective against dementia. Instead, they highlight the importance of considering weight loss from midlife to late life in conjunction with late-life BMI in dementia risk stratification.